Tasurgratinib

DB21222InvestigationalSmall molecule

Tasurgratinib is a small molecule drug. The usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor. Tasurgratinib is under... Tasurgratinib is under investigation in clinical trial NCT04962867 (NCCH2006/MK010 Trial (FORTUNE Trial)).

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 1, and Fibroblast growth factor receptor 3
Curator reviewed
Formula / weight: C₃₂H₃₇N₅O₆ · 587.677 g/mol (avg)
Code names: E-7090

Resolves to

Compound

UNIITN7CUD1NGACAS1622204-21-0ChEMBLCHEMBL3686884ChEBI755704PubChem78323434

Structure

InChIKeyIBHOLSBDZMIPPT-UHFFFAOYSA-NSMILESCNC(=O)N1C=CC2=CC(OC3=CC=NC(NC(=O)C4=CC=C(C=C4)C4CCN(CCO)CC4)=C3)=C(OCCOC)C=C12

Targets

P21802FGFR2P11362FGFR1P22607FGFR3

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tasurgratinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account